Coronavirus Disease 2019 Infection among Children: Pathogenesis, Treatment, and Outcome

Krishna Rao Gurugubelli1 Ballambattu Vishnu Bhat2

1 Department of Biochemistry, AIIMS, Mangalagiri, JIPMER, Puducherry, India
2 Department of Pediatrics and Neonatology, AVMC & H, Kirumambakkam, Puducherry, India

Address for correspondence Ballambattu Vishnu Bhat, MD, Department of Pediatrics and Neonatology, AVMC&H, Kirumambakkam, Puducherry – 607403, India (e-mail: drvishnubhat@yahoo.com).

Introduction

Coronavirus disease 2019 (COVID-19) is a life-threatening disease causing massive public health problem worldwide. It has originated from Wuhan, China and is spreading in both developing and developed countries. The epidemic impact depends on the number of infected individuals, mode of transmission, and spectrum of clinical severity.1 The target organ for COVID-19 is believed to be the lungs; however, patients often have evidence of multiorgan dysfunction such as affecting heart, liver, kidney, stomach, brain, blood, and immune system.2,3 The COVID-19 infection causes clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus (SARS-CoV). It is often associated with intensive care unit admission and high mortality. Patients usually develop upper respiratory tract signs and symptoms initially.3 About 2% of the people infected with COVID-19 are healthy carriers and this virus plays a key role in 5 to 10% of acute respiratory infections. Phylogenetic analysis revealed that "A and B" lineage of β-CoV (HCoVs family) can cause common cold, respiratory tract infections, and extra respiratory infections with increased clinical severity, respectively (►Fig. 1).4

Epidemiology

Epidemiological classification of COVID-19 includes those at high, moderate, and low risk. High risk consists of close contact with confirmed COVID-19 cases within 14 days after...
onset. Medium risk consists of COVID-19 outbreak clusters in residential areas and community. Low risk consists of people in endemic areas outside the source of epidemic. COVID-19 clinical manifestations in children may be less severe compared with adults. This may be related to both host factors and exposure. Usually, children who are well cared for at home might have relatively less chances to expose themselves to pathogens and patients who are sick. Children frequently experience respiratory infections and may have higher level of antibody against viruses than adults. The immune system of children is in developing stage and it responds to pathogens differently compared with adult immune system. Some studies reported that boys are more vulnerable to COVID-19 compared with girls. But Dong et al did not observe significant difference between two genders. Common circulating HCoVs are seen in 4 to 6% of children hospitalized from acute respiratory tract infections. Children with age less than 3 years and those with heart disease are most often symptomatic. In later life, reinfections are more common. Compared with other respiratory tract infections, there is no decrease in HCoVs with increasing age. Children with COVID-19 may be mostly asymptomatic or only have gastrointestinal symptoms, pharyngitis, or cough.

**Pathogenesis**

Structural analysis during SARS-CoV outbreak in 2002 has revealed specific molecular level interactions between spike protein receptor binding domain of SARS-CoV and its receptor angiotensin-converting enzyme 2 (ACE-2) in the host. Based on the available evidence on SARS-CoV and recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequence, Wan et al suggested that COVID-19 uses ACE-2 as its receptor. While binding certain critical residues in COVID-19 receptor binding motif (Gln493), it brings out positive interactions with human ACE-2 leading to infectivity. The phylogenetic analysis has indicated the origin of 2019-nCoV from a bat and recognizes ACE-2 from a wide variety of animal species suggesting that all these species as potential intermediate hosts for novel coronavirus infections. ACE-2 receptors are expressed on epithelial cells of nasal cavity, type 2 alveolar cells of lungs, heart, kidney, and gastrointestinal tract. Lungs are more vulnerable to COVID-19 because of their large surface area. Patients with chronic obstructive pulmonary disease (COPD) are known to have increased expression of ACE-2 receptors leading to severe lung disease. Li and Zhang reported that ACE-2 expression is not significantly different between healthy individuals and cases with COPD and asthma.
Alzamora et al have identified COVID-19 in nasopharyngeal swab (16 and 48 hours sample by real-time reverse transcription [RT-PCR]) of neonate and confirmed COVID-19 positivity, but the antibody levels were not elevated up to 5 days of life, which might be due to impaired antibodies and cytokine production in the neonatal period, especially seen in preterm neonates.\textsuperscript{18}

Specific IgM antibodies in blood with negative nasopharyngeal swab test (by RT-PCR) have been reported in newborn babies immediately after birth from COVID-19 infected mothers. Since IgM—due to its pentameric structure—does not usually cross the placental barrier, this response indicates transmission of novel coronavirus to the fetus from mother. However, false positive testing may also occur due to alterations in placenta permitting the transmission of IgM.\textsuperscript{13,19}

Chen et al reported that COVID-19 nucleic acid titers in placentas of COVID-19 infected mother were undetectable.\textsuperscript{20} Transcriptomic study by Li et al reported extensive repression of COVID-19 receptors (ACE-2) on maternal–fetal interface and fetal organs like lung, liver, and heart.\textsuperscript{21} Wrapp et al reported that, the novel 2019-nCoVs binds with higher affinity than SARS-CoVs, which suggests that COVID-19 is more likely to attack placenta and increase the chances of miscarriage.\textsuperscript{22} However, it remains unclear and further studies are required to confirm this. Celik et al reported that absence of caveolin expression in syncytiotrophoblasts prevents the vertical transmission of COVID-19. Caveolae are “Ω” shaped structure present on cell membrane. It contains caveolin-1 protein that acts as a binding site for COVID-19. Usually, this protein expressed on the alveolo–capillary barrier, but not on the syncytiotrophoblast barrier.\textsuperscript{23}

The most likely way of COVID-19 transmission from mother to infant is likely through respiratory droplets. Hence, during the time of delivery, immediate cord clamping, isolation of neonates, and avoiding skin-to-skin contact with mother can reduce the neonatal infection.\textsuperscript{24} COVID-19 may exist for a longer duration in children's gastrointestinal tract compared with the respiratory system. Continual shedding of COVID-19 in stools of infected children suggests that the virus might be transmitted through contaminated fomites.\textsuperscript{25}

Since the virus has not been isolated from breast milk, breastfeeding can be done with social distancing or expressed breast milk feeding to the baby by another care taker using cup and spoon.

**Immunological Mechanisms**

Successful pregnancy depends on well-tuned immune adaptations, instead of constant immune suppression. Maternal immune system adapted to changes according to the fetal growth and development across different gestational ages such as pro-inflammatory (embryo implantation and placentation), anti-inflammatory (fetal growth), and second pro-inflammatory responses (adapting initiation and parturition) at first, second, and third trimester, respectively.\textsuperscript{26} Cytokine storm is a well-defined feature associated with the COVID-19 infection, which is characterized by elevated plasma concentrations of interleukin (IL)-10, IL-7, IL-2, tumor necrosis factor-\(\alpha\),
interferon γ-inducible protein 10, macrophage inflammatory protein 1 α, granulocyte-colony stimulating factor, and monocyte chemo attractant protein 1. Usually, pregnant women during first and third trimester are at pro-inflammatory state; hence, the cytokine storm induced by COVID-19 may cause harsh inflammatory response in women, which causes postnatal neuronal dysfunctions. Clinical Manifestations

In children, high index of suspicion is required to diagnose COVID-19, as the clinical manifestations are similar to other common viral infections. Generally, 95% of the children show mild or no symptoms. The commonly reported symptoms are fever, sore throat, cough, nasal congestion, and discharge from nose. Respiratory symptoms are least common while gastrointestinal symptoms are more common in children compared with adults. Febrile seizures have been reported rarely. Tachypnea is the most common sign of lower respiratory tract involvement in newborns. The severity of illness is usually mild in children, but rarely they may present as sepsis and encephalitis. Compared with older children, severe illness is more common in neonates with crying, irritability, silent hypoxia, neurological symptoms, and feeding difficulties. Concurrent infections with Epstein–Barr virus, rhinoviruses, enterovirus, respiratory syncytial virus, streptococcus pneumonia, and non-SARS coronaviruses are more common in children. Pediatric patients are different from adults in that they often have elevated procalcitonin levels and consolidation in lung with surrounding halo sign on imaging. It indicates that coinfection is more prevalent in pediatric patients. Perinatal novel coronavirus infection may have severe impact on neonates, such as respiratory distress, premature labor, thrombocytopenia, fetal distress, abnormal liver function, and occasionally death.

Other Unusual Features

Cytokine Release Syndrome

It can cause multiple organ dysfunction syndrome leading to death with elevated pro-inflammatory cytokines and inflammatory markers. This complication has rarely been reported in children.

Multisystem Inflammatory Syndrome in Children

A cluster of adolescents and children who developed a prominent inflammatory response systemically with occasional deaths have been reported in some places of United States and Europe. This inflammatory response shares common features with bacterial meningitis, macrophage activation syndromes, Kawasaki disease, and toxic shock syndrome. MIS-C appears to be a postinfectious cytokine storm with prolonged fever (5 days or more), mucocutaneous inflammation signs, hypotension secondary to myocardial dysfunction, evidence of coagulopathy, acute gastrointestinal problems, and elevated inflammatory markers such as erythrocyte sedimentation rate, C-reactive protein, and procalcitonin. However, often there is no evidence of bacterial infection. These patients often had an evidence of novel coronavirus in the form of positive RT-PCR, antigen, or antibody test positivity. The clinical and biochemical aspects of MIS-C are different from Kawasaki disease. Belhadjer et al reported 35 children affected with MIS-C syndrome who had features of fever and acute heart failure, 28% of them had comorbidities with prominent gastrointestinal symptoms with release of markers as a result of cytokine storm and macrophage activation. However, it is unclear whether these manifestations are part of Kawasaki disease with COVID-19 as the stimulating agent or a different syndrome.

Rhabdomyolysis

It is the leakage of muscle content into extracellular fluid because of skeletal muscle breakdown. Gufón et al observed elevated creatine kinase levels in COVID-19, associated with rhabdomyolysis in a pediatric case.

Pregnancy-Related Complications

The detrimental effects on the neonates including thrombocytopenia, fetal distress, abnormal liver functions, premature labor, and respiratory distress have been reported. But it is uncertain whether these adverse effects are caused by maternal COVID-19 infection or by direct infection of neopate. Maternal mortality has been documented along with oligohydramnios, perinatal death, preterm birth, miscarriage (including a case in the second trimester), intrauterine growth restriction, ectopic pregnancy, and neonatal death.

Imaging Findings

The radiographic and CT findings play an important role in the COVID-19 diagnosis. Wang et al observed that some children with no clinical symptoms had nonspecific positive chest computed tomography (CT) findings. Other identified findings include interstitial abnormalities, local and bilateral patchy shadowing, ground glass opacities (GGO), and consolidation. Li et al observed that chest CT imaging features of COVID-19 infection in preschool children were different from those in adult patients as they had smaller pulmonary consolidations, no ground glass opacities (GGO), and presence of bronchitis/bronchial pneumonia-like changes. Additionally, small airway lesions with uneven lucency of the regional lung lobe or multiple small cystic lucent shadows in the bilateral lower lungs were observed. Chest CT manifestations in preschool children were mostly mild with better outcome after treatment. Normal findings on chest CT were observed in pediatric patients with mild COVID-19 illness; however, few of them had disease progression on CT scan showing more localized GGO extent, lower GGO attenuation, and relatively rare interlobular septal thickening. Feng et al reported smaller nodular GGO in COVID-19 pediatric patients. However, other features such as interlobular septa thickening, consolidation, GGO with consolidation have also been observed. Other chest imaging findings reported in these pediatric patients include interstitial changes, diffuse consolidation (white lung),
bronchopneumonia with mycoplasma infection and Pleural effusion. Lung lesions completely resolve with recovery in most patients. However, to protect the children from radiation, the usage of chest CT in pediatric patients with COVID-19 should be more cautious.\(^5\)

**Treatment Modalities**

As the vaccine is still being developed against SARS-n-CoV-2 and with the lack of a definitive therapy specifically targeting this virus, the treatment is mainly symptomatic and supportive. Oxygen therapy is the most efficient treatment in critically ill neonates and children. Early treatment reduces the complications like acute respiratory distress syndrome and multiorgan dysfunction. There is no clear-cut evidence of definite improvement with antiviral therapy in pediatric COVID-19 cases till date.\(^59\) Remdesivir, favipiravir, and ribavirin are the nucleotide analogs effective against premature termination of COVID-19 RNA transcriptome. Jean et al reported that remdesivir (200 - mg/day 1 and 100 mg/day 2 onward) was used to treat a COVID-19 patient with progressive pulmonary manifestations on the 7th day of hospitalization with clinical improvement. Side-effects such as nausea, vomiting, including severe ones like rectal hemorrhage, and hepatic toxicity have been reported recently. Favipiravir (1,600 mg/twice/1 day, 600 mg/twice/2–5 days, and 600 mg/once on the 6th day) was used for the treatment of COVID-19 in China. Ribavirin is also an antiviral drug, but it may cause anemia and harmful in patients with respiratory distress.\(^60\)

Corticosteroids were used to treat patients with COVID-19 infection in a few reports. Its possible benefit is by reducing the inflammatory induced lung injury;\(^27\) however, few studies suggested that treating with corticosteroids may not have any effect on mortality rather it may delay the viral clearance in SARS and middle east respiratory syndrome patients.\(^61–63\) WHO interim guidelines do not suggest corticosteroids therapy except in severe cases.\(^64\) Intravenous immunoglobulin (IVIG) is being tried to treat the neonates and severely ill children.\(^65\) Recent study reported that Bruton’s tyrosine kinase (BTK) controls the macrophage activation leading to elevated levels of IL-6 in COVID-19 adults; hence, acalabrutinib (selective BTK inhibitor) may be used as a treatment option in severe SARS-n-CoV-2 infection.\(^56\) However, its use has not shown benefit in neonatal and pediatric cases. Few studies reported that COVID-19 host cell entry through spike proteins have offered insight for vaccine development and usage of various protease inhibitors.\(^67\) Either lopinavir (400 mg/twice/14 days) or ritonavir (100 mg/twice/14 days) alone may not be beneficial for COVID-19 treatment; however, the regimen of lopinavir and ritonavir together may be effective. Alternatively, hydroxychloroquine (200 mg/thrice/daily) plus azithromycin (500 mg/1 day, followed by 250 mg once daily on 2–5 days) has emerged as an alternate treatment option with excellent clinical efficacy in Chinese patients with COVID-19 infection.\(^60\) Several studies reported the usage of convalescent plasma (CP) therapy for SARS-n-CoV-2 treatment. It improved oxygenation and lymphocyte count and reduced inflammatory markers/viral load.\(^68\) Duan et al described improvement in several parameters compared with pretransfusion including increased lymphocyte counts (0.65 × 10^9/L vs. 0.76 × 10^9/L) and decreased C-reactive protein (55.98 vs. 18.13 mg/L). There was improvement in the lung lesions within 7 days on radiological examinations. Additionally, undetectable viral load in patients with viremia and no complications were observed.\(^69\) The mechanism of action is not fully understood. However, anti-SARS-IgM and IgG directly neutralizes the virus.\(^70\) However, it is important to formulate individual therapy regimens. CP can only be used empirically by strict screening for indications monitoring the transfusion process and with strict recording of outcome.\(^71\) The mandatory conditions for donation of CP are that the donor must have been diagnosed with COVID-19 infection and recovered at least 14 days earlier, male and nulliparous female patients with negative history of blood transfusion. Careful evaluation of the donor is recommended. The antibody titer should be at least 1:320, with negative results of biological qualification tests, hepatitis A, B, parvo virus, and proper maintenance of CP units.\(^72\) But most of these studies were described in adults. It is uncertain whether the CP therapy will be effective in critically ill pediatric patients.

**Prognostic Factors**

Laboratory abnormalities were not widely reported in COVID-19 infected children compared with adult COVID-19 patients. The burden of the disease severity seems to be low in children compared with adults. Dong et al reported that 10% of the neonates that tested positive for SARS-nCoV-2 probably are at high risk requiring ventilator support and other interventions.\(^6\) Children with adverse SARS-nCoV-2 clinical course show elevated procalcitonin, CRP, and LDH levels similar to adult patients with COVID-19.\(^73\) Additionally, positive D-dimer, elevated prothrombin time were observed in COVID-19 infected children.\(^74\) IL-6, IL-10, and serum ferritin levels may help to prognosticate among infected children. But none of the studies have reported elevated serum ferritin levels in neonates.\(^75\) Li et al reported that the children with SARS-n-cov-2 pneumonia had elevated levels of CD8+ T cells compared with those with respiratory syncytial virus pneumonia. This activation plays a crucial role in the development of symptoms among children with SARS-n-COV-2 pneumonia; hence, it could be used as a biomarker to predict the prognosis of COVID-19 infection.\(^76\)

**Conclusion**

COVID-19 affects people of all age groups. Most of the neonatal and pediatric cases are seen with mild symptoms as clusters in family, usually have rapid recovery and good prognosis. Early isolation of neonate from infected mother should be done since there no definite evidence of intrauterine vertical transmission. Breast milk feeding can be given since there is no evidence of virus in breast milk. Moreover, vaccine development and identification of effective antiviral drugs against COVID-19 are important for improving the outcome.
COVID-19 infection among children: pathogenesis, treatment and outcome  Gurugubelli, Ballambattu

Funding
None.

Conflicts of Interest
None declared.

References

40. New York State Governor Cuomo announces state is helping to develop the national criteria for identifying and responding to COVID-related illness in children Available at: https://www.governor.ny.gov/news/governor-cuomo-announces-state-helping-
developed national criteria identifying and responding. Accessed September 1, 2020


70. Yuen KS, Ye ZW, Fung SY, Chan CP, Jin DY. SARS-CoV-2 and COVID-19: the most important research questions. Cell Biosci 2020;10:40


